LifeStance Health Group (NASDAQ:LFST) Posts Earnings Results, Beats Expectations By $0.03 EPS

Posted by on Aug 8th, 2026

LifeStance Health Group (NASDAQ:LFST – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03, FiscalAI reports. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The firm had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. During the same quarter last year, the company posted ($0.01) EPS. The firm’s quarterly revenue was up 26.1% on a year-over-year basis.

Here are the key takeaways from LifeStance Health Group’s conference call:

  • Positive Sentiment: LifeStance reported strong second-quarter performance, with revenue up 26% to $435 million, visits rising 19% to 2.6 million, and Adjusted EBITDA nearly doubling to $66 million. Adjusted EBITDA margin reached 15.2%, up more than 500 basis points year over year.
  • Positive Sentiment: Management raised full-year 2026 guidance, now projecting revenue of $1.685 billion-$1.725 billion and Adjusted EBITDA of $215 million-$235 million. The midpoint implies 20% revenue growth and a 13.2% Adjusted EBITDA margin.
  • Positive Sentiment: Clinician additions and productivity remain key growth drivers, with 193 net clinicians added in the quarter to reach 8,542, while visits per average clinician increased 7% for the third consecutive quarter. Management said only about 70% of clinician-provided capacity is currently being utilized, indicating further runway.
  • Positive Sentiment: Specialty services, including TMS and SPRAVATO, are expanding and generated roughly $50 million of revenue last year, with expected growth of about 40% in 2026. The company also sees significant opportunity from geographic expansion, tuck-in acquisitions, AI-enabled tools, and a planned 2027 EHR rollout.
  • Negative Sentiment: Third-quarter Adjusted EBITDA guidance of $49 million-$59 million implies a sequential decline as LifeStance increases spending on technology, patient acquisition, clinical excellence, compensation, and support staff. Management also cautioned that the phased EHR implementation could cause a temporary productivity dip.

LifeStance Health Group Stock Up 1.7%

Shares of LFST stock traded up $0.18 on Friday, reaching $10.84. 3,793,084 shares of the stock were exchanged, compared to its average volume of 3,253,660. The company has a market capitalization of $4.20 billion, a price-to-earnings ratio of 83.39 and a beta of 1.14. The business’s 50 day moving average price is $9.95 and its 200 day moving average price is $8.05. The company has a current ratio of 1.38, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. LifeStance Health Group has a twelve month low of $3.90 and a twelve month high of $11.76.

Insider Buying and Selling at LifeStance Health Group

In other news, Director Darren M. Black sold 5,899,661 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $47,315,281.22. Following the transaction, the director owned 23,310,115 shares in the company, valued at approximately $186,947,122.30. This represents a 20.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert Bessler sold 894,337 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the transaction, the director owned 539,763 shares in the company, valued at approximately $5,467,799.19. The trade was a 62.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,612,394 shares of company stock worth $62,938,451 over the last ninety days. Corporate insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. increased its stake in LifeStance Health Group by 6.9% in the fourth quarter. Invesco Ltd. now owns 205,486 shares of the company’s stock valued at $1,447,000 after purchasing an additional 13,177 shares during the last quarter. Vident Advisory LLC boosted its position in shares of LifeStance Health Group by 148.8% in the 4th quarter. Vident Advisory LLC now owns 37,462 shares of the company’s stock valued at $264,000 after purchasing an additional 22,406 shares during the period. XTX Topco Ltd acquired a new stake in shares of LifeStance Health Group in the 4th quarter valued at about $96,000. Zacks Investment Management grew its stake in LifeStance Health Group by 33.1% during the 4th quarter. Zacks Investment Management now owns 45,291 shares of the company’s stock worth $319,000 after buying an additional 11,270 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in LifeStance Health Group by 58.8% during the 4th quarter. Janus Henderson Group PLC now owns 94,500 shares of the company’s stock worth $666,000 after buying an additional 35,000 shares during the last quarter. 85.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on LFST shares. Barclays boosted their target price on LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. The Goldman Sachs Group started coverage on shares of LifeStance Health Group in a research note on Friday, June 5th. They issued a “neutral” rating and a $9.00 price target for the company. Wall Street Zen cut LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, KeyCorp boosted their target price on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, LifeStance Health Group has a consensus rating of “Moderate Buy” and an average price target of $11.62.

View Our Latest Research Report on LFST

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

  • Positive Sentiment: BTIG raises price target: BTIG Research raised its LFST price target from $15 to $16 and initiated a “buy” rating, implying substantial potential appreciation from the referenced $10.84 price. Benzinga price target report
  • Positive Sentiment: Q2 earnings beat expectations: LifeStance reported adjusted earnings of $0.06 per share, exceeding the $0.03 consensus estimate, compared with a $0.01 loss in the year-earlier quarter. Revenue rose 26.1% year over year to approximately $435.4 million, ahead of the $414.6 million analyst forecast. LifeStance Q2 earnings report
  • Positive Sentiment: Profitability improved sharply: Net income reached $23.6 million versus a $3.8 million loss a year ago, while adjusted EBITDA nearly doubled to $66.0 million. Visit volume increased 19% and the clinician base grew 11% to 8,542, supporting the company’s growth outlook. LifeStance financial results release
  • Positive Sentiment: Full-year outlook raised: Management increased 2026 revenue guidance to $1.685 billion-$1.725 billion, Center Margin guidance to $570 million-$594 million and adjusted EBITDA guidance to $215 million-$235 million. Third-quarter revenue is projected at $420 million-$440 million, above the $417.7 million consensus estimate.
  • Positive Sentiment: Share repurchase authorization: The board approved a new program allowing up to $100 million of common-stock repurchases, potentially supporting per-share results and signaling management confidence in the company’s valuation.
  • Neutral Sentiment: Balance-sheet considerations: LifeStance generated $99.9 million of operating cash flow in Q2 and ended the period with $225.9 million in cash, but reported $259.0 million of net long-term debt.
  • Negative Sentiment: Insider selling remains a risk: Recent disclosed insider activity has consisted entirely of sales, including substantial transactions by TPG-related entities and company executives. Continued selling could temper investor enthusiasm despite the strong operating results.

About LifeStance Health Group

(Get Free Report)

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

Featured Stories

Earnings History for LifeStance Health Group (NASDAQ:LFST)

Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.